And recent research published in JAMA Network Open suggests older adults are more likely than their younger peers to discontinue these popular medications
doi: 10.3389/fmicb.2014.00504 134 MurataTOkunoYSatoYWatanabeTKimuraH
By BioPharma Dive staff July 1, 2026 Abivax shares surge as worries subside over immune drugs cancer risk According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern
Patients considering treatment should have an honest discussion with their medical provider about the potential benefits, risks, costs, and long-term expectations before beginning therapy
In recent years, the clinical research of TCM compounds has garnered increased international attention
With years of experience, she ensures personalized and customized treatment for every patient